Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Koh

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
International Journal of Clinical Oncology|September 18, 2024
Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 studyKoji Kato, Sosuke Nakamura, Akira Wakana, et al.
Cancer Research|August 3, 2005
Halogenated thymidine analogues restore the expression of silenced genes without demethylationJun Fan, Ei-ichi Kodama, Yasuhiro Koh, et al.
Journal of Chemical Information and Modeling|November 26, 2009
Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water modelDebananda Das, Yasuhiro Koh, Yasushi Tojo, et al.
Clinical Lung Cancer|January 7, 2019
A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Yasuhiro Koh, et al.
Cancer Science|April 5, 2014
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cellsMasakuni Serizawa, Haruyasu Murakami, Masaru Watanabe, et al.
Anticancer Research|April 3, 2020
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma CellsTakehito Shukuya, Jun Oyanagi, Masakuni Serizawa, et al.
Current Opinion in Pharmacology|September 8, 2004
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infectionKenji Maeda, Hirotomo Nakata, Hiromi Ogata, et al.
Scientific Reports|July 10, 2019
Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decompositionMasayuki Amano, Haydar Bulut, Sadahiro Tamiya, et al.
Cancer Science|December 15, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft modelsFumiko Taguchi, Yasuhiro Koh, Fumiaki Koizumi, et al.
The Journal of Biological Chemistry|March 27, 2004
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motilityYukiko Ueda, Shizhen Wang, Nancy Dumont, et al.
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
International Journal of Clinical Oncology|September 18, 2024
Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 studyKoji Kato, Sosuke Nakamura, Akira Wakana, et al.
Cancer Research|August 3, 2005
Halogenated thymidine analogues restore the expression of silenced genes without demethylationJun Fan, Ei-ichi Kodama, Yasuhiro Koh, et al.
Journal of Chemical Information and Modeling|November 26, 2009
Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water modelDebananda Das, Yasuhiro Koh, Yasushi Tojo, et al.
Clinical Lung Cancer|January 7, 2019
A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L)Hiroaki Akamatsu, Shunsuke Teraoka, Yasuhiro Koh, et al.
Cancer Science|April 5, 2014
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cellsMasakuni Serizawa, Haruyasu Murakami, Masaru Watanabe, et al.
Anticancer Research|April 3, 2020
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma CellsTakehito Shukuya, Jun Oyanagi, Masakuni Serizawa, et al.
Current Opinion in Pharmacology|September 8, 2004
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infectionKenji Maeda, Hirotomo Nakata, Hiromi Ogata, et al.
Scientific Reports|July 10, 2019
Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decompositionMasayuki Amano, Haydar Bulut, Sadahiro Tamiya, et al.
Cancer Science|December 15, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft modelsFumiko Taguchi, Yasuhiro Koh, Fumiaki Koizumi, et al.
The Journal of Biological Chemistry|March 27, 2004
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motilityYukiko Ueda, Shizhen Wang, Nancy Dumont, et al.
Pageof 15